Subject(s)
Antiviral Agents/therapeutic use , HIV Infections/complications , Hepatitis C/drug therapy , Hepatitis C/virology , Adult , Aged , Coinfection/drug therapy , Coinfection/virology , Female , Hepacivirus/isolation & purification , Hepatitis C/complications , Hepatitis C/epidemiology , Humans , Interferons/therapeutic use , Male , Middle Aged , Missouri , Retrospective Studies , Sustained Virologic Response , Treatment OutcomeABSTRACT
Options for treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections are extremely limited. Minocycline intravenous is active against many MDR strains of Acinetobacter, and Clinical and Laboratory Standards Institute breakpoints exist to guide interpretation of minocycline susceptibility results with Acinetobacter. In addition, minocycline intravenous holds a US Food and Drug Administration indication for treatment of infections caused by Acinetobacter. There is an accumulating amount of literature reporting successful use of minocycline intravenous for treatment of serious MDR Acinetobacter infections, particularly for nosocomial pneumonia. These results, coupled with the generally favorable tolerability of minocycline intravenous, support its use as a viable therapeutic option for treatment of MDR Acinetobacter infections.
